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The aim of this study was to assess the activity and toxicity of a platinum-based treatment on a group of patients with unknown
primary tumours (UPTs). Patients with a diagnosis of UPT underwent a standard diagnostic procedure. Treatment was started within
2 weeks from diagnosis and consisted of carboplatin 400mgm
 2 day 1, doxorubicin 50mgm
 2 day 1, etoposide 100mgm
 2 days
1–3, every 21 days. Response was evaluated after three courses and treatment continued in case of objective response (OR) or
symptom control. A total of 102 patients were eligible. The median age was 59 years, sex male/female 54/48, histology was mainly
adenocarcinoma or poorly differentiated carcinoma. Nodes, bone, liver and lung were the most frequently involved sites. In all, 79
patients received at least three courses of treatment; 26 patients received six courses or more. Six complete responses and 21 partial
responses were observed, for a total of 27 of 102 ORs or 26.5% (95% confidence interval 18.2–36.1%). The median survival was 9
months and median progression-free survival was 4 months. Toxicity was moderate to severe, with 57.8% of patients experiencing
grade III–IV haematological toxicity, mainly leucopenia. The regimen employed has shown activity in tumours of unknown primary
site, but was associated with significant toxicity. Such toxicity may be considered unjustified, given the large proportion of patients
with tumours not likely to respond. Efforts should therefore be addressed to identify predictors of response to chemotherapy, thus
limiting aggressive treatment to those patients who could benefit from it.
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Unknown primary tumours (UPTs) are now recognised as an
autonomous, although heterogeneous, nosographic entity, with
considerable clinical relevance, as they account for 5% of all
tumours. Until recently they were approached with more emphasis
on diagnosis than on treatment. Much emphasis was placed on
trying to ascertain the site of origin of the tumour. This approach
is slowly being discarded, at least in reported series, although it
widely resists in clinical practice, in particular in non-specialised
centres. There are two main reasons for abandoning extensive
investigation in an attempt to find the site of origin. Extensive
diagnostic procedures cause discomfort for the patient, require
time and cause delay of treatment. In addition, they are often
fruitless (Hainsworth and Greco, 1993; Abbruzzese et al, 1995;
Schapira and Jarrett, 1995).
For the minority of tumours that have been identified in the last
two decades as being potentially sensitive to chemotherapy (van
der Gaast et al, 1990; Pavlidis et al, 1992; Abbruzzese et al, 1995;
Lenzi et al, 1997; Greco and Hainsworth, 2001b), the diagnostic
procedures will delay these patients from receiving effective
treatment.
By restricting diagnostic procedures to a minimum, and with an
early start of chemotherapy, median survival has improved from
3–6 months of the past (Altman and Cadman, 1986; Alberts et al,
1989) to around 1 year in recently reported series (Briasoulis et al,
2000; Greco et al, 2000a).
We have conducted a multicentre phase II trial in patients with
UPT, where diagnostic procedures were limited and where
treatment was started soon after presentation. Although in autopsy
series the majority of patients with UPT are diagnosed with
diseases poorly responsive to treatment (Nystrom et al, 1977),
there is a substantial minority of patients with primary tumours
that are sensitive to chemotherapy, such as germ cell tumours,
ovarian and breast cancer. The regimen chosen for this study, a
combination of carboplatin, doxorubicin and etoposide, contains
drugs active against these more chemosensitive tumours, and
employed at dosages potentially able to induce major responses
We considered that if an improvement of response rate occurred,
this might result in improved outcome for an unselected group of
patients with UPTs, and that this would justify the anticipated
toxicity of the regimen.
This paper describes the results with emphasis on response to
treatment, toxicity and survival.
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lPATIENTS AND METHODS
Patients were enrolled in the study if they had a histologically
confirmed diagnosis of carcinoma, adenocarcinoma or undiffer-
entiated tumour and no evidence of the site of origin based on
routine haematological and biochemical investigation, tumour
markers, chest X-ray and abdominal ultrasound. This initial
investigation was then completed by CT of abdomen and thorax,
and bone scan. Patients with carcinoma or undifferentiated
tumour in cervical nodes as the only site of disease were excluded,
as they usually deserve specific diagnostic and therapeutic
procedures as for head and neck tumours. Other eligibility criteria
were: bidimensionally measurable disease and/or elevated tumour
markers; age 70 years or less, ECOG performance status p2; and
adequate bone marrow (WBC X4000ml
 1; platelets
X100000ml
 1), renal (creatinine and urea p1.5 N, upper limit
of normal) and liver function (bilirubin p1.5 N; liver enzymes
o3 N). Patients were excluded if there was a previous diagnosis
of cancer at known sites, coexistent cardiac failure or ischaemia,
psychiatric disorder or other severe medical illness and less than 3
months of life expectancy.
Following initial workup and assessment of all measurable
disease, other diagnostic procedures were those dictated by clinical
presentation. The intention was to start treatment within 2 weeks
from the diagnosis of UPT.
The pathology workup included immunohistochemistry and, in
a limited number of cases, electron microscopy to ascertain
epithelial differentiation in some lesions composed of small cells.
Immunohistochemistry was carried out on specimens fixed
routinely in 10% neutral-buffered formalin for 24h. Primary
antibody was incubated at 41C for 16–18h; avidin–biotin–
peroxidase complex method was used as a immunodetection
method. A variety of antibody reagents were used: cytokeratins –
AE1/AE3, CAM 5.2, CK 20, CK 7; epithelial membrane antigen;
vimentin; carcinoembryonic antigen; calretinin; S100 protein –
placental alkaline phosphatase; thyroglobulin; prostate-specific
antigen (PSA); MOC-31; estrogen receptor protein; CA-125; CA
19.9; and tumour-associated glycoprotein (B72.3). Pathology
reports were reviewed and classified by one of the authors (RM);
no centralised pathology review was carried out.
Patients were treated as outpatients with the following
chemotherapy regimen: carboplatin 400mgm
 2 day 1, doxorubi-
cin 50mgm
 2 day 1 and etoposide 100mgm
 2 days 1–3; cycles
were repeated every 21 days. At subsequent cycles, if haematolo-
gical parameters had not recovered by day 22, treatment was
delayed for 1 week. Since this was common, most centres adopted
a 28-day interval for each cycle. Reduction of doses by 25% was
mandatory at the first cycle if patients had advanced age (465),
poor performance status (ECOG 2), multiple organ involvement by
the disease, poor renal, cardiac or liver function. This reduction
was often maintained throughout all courses based on tolerance. In
patients starting with full doses of drugs, a dose reduction of 25%
was also planned for subsequent administrations in case of grade
3–4 leucopenia or thrombocytopenia. The use of growth factors on
an individual basis was left to the discretion of attending
physicians. During therapy, blood counts were not, as a rule,
monitored on a weekly basis.
Concomitant antiemetic therapy included 5-hydroxytryptamine-
3 antagonists and dexamethasone.
Response was evaluated after three cycles of therapy according
to the WHO criteria. Stable and responding patients were
subjected to additional cycles based on clinical evaluation.
Subsequent treatment in the case of tumour progression at any
time was at the discretion of the attending physician.
Response was based on two-dimensional measurement of all
sites of disease. Complete response (CR) was complete disappear-
ance of tumour, partial response (PR) reduction of 50% or better
of the sum of products of the diameters, stable disease (SD)
reduction lower than 50% or less than 25% increase, progressive
disease (PD) increase of more than 25% or appearance of new
lesions. Survival was calculated from entry in the study till the end
of follow-up or death. Progression-free survival was calculated
from entry in the study to progression or death from disease (or
end of follow-up if not progressed). Toxicity was evaluated
according to the WHO criteria (Miller et al, 1981).
Statistical evaluation included analysis of survival (Kaplan–
Meier), comparison of survival curves (log-rank test) and w
2 test to
assess association between baseline characteristics and toxicity.
Carboplatin dosages were converted for statistical purposes to
AUC dosing by the Cockroft–Gault (Cockcroft and Gault, 1976)
and Calvert (Calvert et al, 1989) formulas.
The study was started in January 1991 as a three-institutions
study (Ancona, Verona, Pesaro), and was open by the end of the
year to the other collaborating centres. Accrual was halted in
December 1996; follow-up data were collected on 31st December
2002.
The study was approved by the Ethical Committee of University
of Ancona. Written informed consent was requested from patients
for entry in the study.
RESULTS
A total of 113 patients were registered in the study. Of these, 11
patients were judged not eligible: seven because of a previous
diagnosis of cancer at known sites, three because they had poorly
differentiated carcinoma in cervical lymph nodes as the only site of
disease. In one patient, who started treatment before completion of
initial workup, abnormal PSA levels led quickly to appropriate
diagnostic procedures and to the discovery of the prostatic origin
of the tumour. Three patients who exceeded the age limit but who
were judged by their physicians to be fit to receive the proposed
treatment were included in the analysis.
In all, 102 patients were evaluated; the median age was 59 years
(range 25–73 years), male/female ratio of 1.12 (54/48); 51 patients
had a performance status ECOG 0, 43 patients ECOG 1, eight
patients ECOG 2. Histology was well-differentiated adenocarcino-
ma (WDA) in 38 cases, poorly differentiated carcinoma or
adenocarcinoma (PDC) in 50, squamous cell carcinoma (SCC) in
four and undifferentiated neoplasms (UN) in 10 cases. The
majority of patients had visceral or bone involvement (60 patients
or 58.8%). Eight female patients had peritoneal disease and three
patients (two of which male) had disease confined to axillary
nodes. Other relevant characteristics of the patients are depicted in
Table 1. A total of 74 patients (72.5%) received at least three
courses of treatment; 26 patients (25.5%) received six courses of
treatment or more.
We observed six CR (5.9%) and 21 PR (20.6%), for a total of 27
of 102 objective responses (OR) or 26.5% (95% confidence interval
(CI) 18.2–36.1%), 23 SD (22.5%) and 46 PD (45.1%) (Table 2).
Response was not assessable in six patients (NA, 5.9%). These were
patients who died with disease before response could be assessed,
and are grouped with nonresponders (intention-to-treat analysis).
At the date of last follow-up (December 2002), 94 patients had
died. Two of them committed suicide, both with progressing
disease.
The median survival was 9 months, with 1-year survival of
35.2%, 2-year survival of 18.1%, 5-year survival of 6.3% and
median progression-free survival of 4 months (Table2 and
Figure 1).
The median survival was 23 months for responders, 11 months
for SD patients and 6 months for nonresponding patients
(Figure 2). The median duration of response was 8 months.
Toxicity was moderate to severe (Table 3), with 58 patients
experiencing grade 3–4 haematological toxicity (mainly leucope-
nia, but also thrombocytopenia and anaemia) and one patient
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Toxicity other than haematological was limited to occasional
gastrointestinal toxicity, while complete reversible alopecia was the
rule. One patient had clinically important disturbance of electro-
lytes and another had transient ECG abnormalities. Details of
doses and toxicity are listed in Table 3. Delivered dose intensity,
due to either poor general conditions or toxicity, was approxi-
mately two-thirds of projected dose intensity (Table 3).
No variable was found associated with toxicity among those
assessed, which included: age, sex, performance status, extension
of disease, liver involvement, abnormality of liver indexes,
calculated AUC for carboplatin and dosage reduction of cytotoxic
drugs (Table 4).
Table 1 Characteristics of the patients (N¼102)
No. of patients %
Age (years)
Median 59
Range 25–73
Sex
Male 54 52.9
Female 48 47.1
Performance status
ECOG 0 51 50.0
ECOG 1 43 42.2
ECOG 2 8 7.8
Histology
WDA 38 37.3
PDC 50 49.0
SCC 4 3.9
UN 10 9.8
Extension
Locoregional 28 27.5
Disseminated 74 72.5
Topography
Supradiaphragmatic 30 29.4
Subdiaphragmatic 29 28.4
Both sides 43 42.2
Number of involved sites
1 29 28.4
2 31 30.4
3 17 16.7
X4 25 24.5
Number of metastases
1 13 12.7
2 6 5.9
3 12 11.8
X4 71 69.6
Main involved sites
Supraclavicular nodes 28 27.5
Hylomediastinal nodes 26 25.5
Abdominal nodes 20 19.6
Bone 31 30.4
Liver 27 26.5
Lung 22 21.6
Ascites 12 11.8
Pleural effusion 10 9.8
Nodes/soft tissues only 42 41.2
Visceral/bone involvement 60 58.8
Main symptoms
Pain 65 63.7
Gastrointestinal 30 29.4
Respiratory 20 19.6
Fever 16 15.7
Weight loss 410% 9 8.8
Laboratory parameters
Hb o12 28 27.5
Any liver index X1.25 N 42 41.2
ALP X1.25 N 21/95 22.1
LDH X1.25 N 26/86 30.2
CEA 45 36/96 37.5
CA 19.9440 25/84 29.8
CA 125440 33/69 47.8
Any epithelial marker abnormal 62 60.8
Any germ cell marker abnormal 9 8.8
ECOG¼Eastern Cooperative Oncology Group; WDA¼well-differentiated adeno-
carcinoma; PDC¼poorly differentiated carcinoma or adenocarcinoma; SCC¼squa-
squamous cell carcinoma; UN¼undifferentiated neoplasms. ALP¼alkaline
phosphatase; LDH¼lactate dehydrogenase; CEA¼carcino embrionic antigen; CA
19.9 and CA 125¼carbohydrate antigens CA 19.9 and CA 125.
Table 2 Results of treatment (N¼102)
No. of patients %
Responses
CR 6 5.9
PR 21 20.6
SD 23 22.5
PD 46 45.1
NA 6 5.9
Duration of response
Median (months) 8
Range 2–102+
Overall survival
Median (months) 9
At 12 months 35.3%
At 5 years 6.3%
Progression-free survival
Median (months) 4
At 12 months 16.3%
At 5 years 3.6%
Grade III–IV toxicity
Anaemia 31 30.4
Leucopenia 48 47.1
Thrombocytopenia 28 27.5
Nonhaematological toxicity 10 9.8
CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progres-
progressive disease; NA¼not assessable.
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Figure 1 Kaplan–Meier estimates of survival and progression-free
survival for the whole group of patients with UPT (n¼102).
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lDISCUSSION
The current approach to management of patients with UPT
consists of only limited diagnostic investigation followed by an
early start of treatment.
With this approach, and with diagnostic and therapeutic
improvements (Greco and Hainsworth, 2001b), prognosis seems
to have improved to some extent. Response rates to chemotherapy
range between 23 and 46% and median survival is between 8 and
11 months (Briasoulis et al, 1998a; Culine et al, 1999; Briasoulis
et al, 2000; Greco et al, 2001a; Culine et al, 2002; Greco et al, 2002).
It is difficult to compare results of different series, because of the
lack of standardised clinical prognostic factors and the limitations
of most of the studies, which include small number of patients,
variable characterisation of clinical features and short observation
period. In general, it appears that more recent chemotherapy
regimens that employ platinum compounds, and often etoposide
or taxanes or both (Briasoulis et al, 1998a; Briasoulis et al, 2000;
Saghatchian et al, 2001; Greco et al, 2001a) are superior, in terms
of response rate, to more traditional drugs (Kelsen et al, 1992; Nole
et al, 1993; Falkson and Cohen, 1998; Lofts et al, 1999).
In the current report, we have treated 102 patients with UPT
with an intensive combination of three drugs (carboplatin,
doxorubicin and etoposide). A similar combination was used by
Briasoulis et al (1998a) with lower dosage of carboplatin
(300mgm
 2) and anthracycline (epirubicin 45mgm
 2). We
selected these drugs on the basis of their known efficacy in those
subsets of UPT that are sensitive to chemotherapy (e.g. germ cell
tumours, ovarian carcinomas). We chose to employ these drugs at
dosages that might produce as great number of major responses as
possible. At these doses toxicity, especially myelosuppression, was
expected. The anticipation of toxicity led to restrictive inclusion
criteria such as age limit, good general condition and normal
organ function, with 92% of patients having ECOG PS of 0 or 1.
We obtained 26.5% of ORs and a median survival of 9 months.
Survival at 1 year was 35.3 and 6.3% at 5 years. These results are
similar to those of other recently published reports (Table 5),
although, as previously indicated, reliable comparison cannot be
made between different series.
Toxicity in our patients was moderate to severe. No factor could
be identified that was associated with major toxicity. In particular,
calculated AUC for carboplatin was not associated with toxicity of
chemotherapy. A dose reduction of 25% was routinely applied to
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Figure 2 Kaplan–Meier estimates of survival for patients with: (A) OR,
n¼27; (B) SD, n¼23; and (C) no response (PD/NA, n¼52). Log-rank
test: a vs b, P¼0.008; a vs c, Po0.001; b vs c, P¼0.003.
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disease and poor organ function. This reduction was recom-
mended at first course, but was often maintained through all
courses of chemotherapy. It is to be noticed that all patients except
two had normal renal function at study entry.
Compared to published series, the regimen we used, employed
in an unselected population of patients with UPTs, resulted in no
appreciable advantage in terms of response and survival. Toxicity
was moderate if compared with the toxicity associated with
regimens currently employed in the treatment of chemosensitive
tumours; on the other hand, it exceeded the toxicity of regimens
employed in tumours where chemotherapy is expected to induce a
limited number of responses.
In our view, using an aggressive approach on unselected patients
with UPT is not supported by our data and should not be
recommended as a routine procedure. Attention should be paid,
instead, to the identification of subsets of patients who may benefit
from this approach.
Table 4 Factors examined for the effect on toxicity
Variable Proportion of patients with grade III–IV toxicity P-value
Age p58/458 years 25/50 (50.0%)/33/52 (63.5%) 0.17
Gender male/female 30/54 (55.6%)/28/48 (58.3%) 0.78
ECOG 0/1–2 29/51 (56.9%)/29/51 (56.9%) 1.00
Locoregional/disseminated disease 14/28 (50.0%)/44/74 (59.5%) 0.39
Disease on one side/both sides of diaphragm 31/59 (52.5%)/27/43 (62.8%) 0.30
One–two metastatic sites/three or more 33/60 (55.0%)/25/42 (59.5%) 0.21
Up to three metastases/four or more 19/31 (61.3%)/39/71 (54.9%) 0.55
No liver involvement/liver involved 46/75 (61.3%) / 12/27 (44.4%) 0.13
No visceral involvement/visceral involvement 26/42 (61.9%)/32/60 (53.3%) 0.39
Normal LDH/abnormal LDH 34/60 (56.7%)/15/26 (57.7%) 0.78
Normal ALP/abnormal ALP 46/74 (62.2%)/9/21 (42.9%) 0.11
Normal liver indexes/abnormal liver indexes 32/59 (54.24%)/25/42 (59.52%) 0.45
No epithelial tumour markers/any marker positive 23/40 (57.5%)/35/62 (56.5%) 0.92
No drug dose reduction/doses reduced 39/70 (55.7%)/19/32 (59.4%) 0.73
CBDCApAUC 8/CBDCA4AUC 8 33/58 (56.9%)/25/44 (56.8%) 0.99
CBDCApAUC 9/CBDCA4AUC 9 39/71 (54.9%)/19/32 (61.3%) 0.55
Note: w
2 test; P-values are reported. ECOG¼Eastern Cooperative Oncology Group; AUC¼area under the curve.
Table 5 Results of recent phase II studies in UPT with platinum-based combinations
Author
Publication
year
No. of
patients Chemotherapy
Follow-up
(months)
Overall
response rate*
(%)
Median survival
(months)
1-year survival
(%)
Becouarn et al 1989 85 CDDP/DOX/5FU/
HMM
36 (max) 21.2 7 25
Rigg et al 1997 30 CBDCA/5FU/FA 2.8–16.6 26.7 7.8 NA
Falkson and Cohen 1998 40 CDDP/EPI/MIT NA 50.0 9.4 NA
Briasoulis et al 1998a 62 CBDCA/EPI/VP16 40 (max) 37 10 NA
Warner et al 1998 33 CBDCA/VP16 os 0.5–33 18.2 5.6 NA
Lofts et al 1999 44 CDDP/5FU/TAM NA 22.7 4 0
Greco et al 2000b 71 CBDCA/PTX/VP16
os
34-50 45.1 11 48
Briasoulis et al 2000 75 CBDCA/PTX/G-
CSF
28 (median) 38.7 13 NA
Greco et al 2000a 26 DTX/CDDP 33 (max) 23.1 8 42
47 DTX/CBDCA 24 (max) 19.1 8 29
Parnis et al 2000 43 CDDP/EPI/5FU 24–72 18.6 5.3 NA
Voog et al 2000 25 CDDP/VP16 NA 32 8 NA
Dowell et al 2001 34 PTX/FA/5FU or
CBDCA/VP16
NA 17.6 6.4 26
Saghatchian et al 2001 30 CDDP/VP16/IFO/
BLM
32 (median) 40 9.4 NA
18 CDDP/5FU/IFN 44 16 NA
Guardiola et al 2001 22 CDDP/DOX/CYT NA 45.5 10.7 NA
Macdonald et al 2002 31 MIT/CDDP/5FU 7–53 27 7.7 28
Culine et al 2002 82 CTX/
DOX+CDDP/
VP16
NA 29.3 10 NA
Greco et al 2002 120 CBDCA/PTX/GEM 8–27 23.3 9 42
Present series 2003 102 CBDCA/DOX/
VP16
61–120 26.5 9 35.3
Note:N A¼not available; *¼by intent-to-treat analysis. BLM¼bleomycin; CBDCA¼carboplatin; CDDP¼cisplatin; CYT¼cytoxan; DOX¼doxorubicin; DTX¼docetaxel;
EPI¼epidoxorubicin; 5FU¼5-fluorouracil; FA¼folinic acid; GEM¼gemcitabine; HMM¼hexamethyl-melamine; IFN¼alfa-interferon; IFO¼ifosfamide; MIT¼mitomycin C;
PTX¼paclitaxel; TAM¼tamoxifen; VP16¼etoposide; UPT¼unknown primary tumours.
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testing of tumour samples, both as an aid to diagnosis and as an
adjunct to available clinical variables that can be used to select
groups of patients well defined with regard to prognosis and
sensitivity to chemotherapy (Bar-Eli et al, 1993; Motzer et al, 1995;
Pavlidis et al, 1995; Briasoulis et al, 1998b; Califano et al, 1999;
Hainsworth et al, 2000).
Newer imaging techniques (Tilanus-Linthorst et al, 1997; Kole
et al, 1998; Lenzi et al, 1998; Schorn et al, 1999; Stevens et al, 1999),
such as breast MRI, positron emission tomography and other
nuclear medicine techniques, that can give clues as to the site of
the primary, presently remain of limited help.
There are important psychological aspects of the management of
this condition. Two of our patients committed suicide. The failure
to identify the site of origin adds to the anxiety and uncertainty of
the condition and its treatment. The need for psychological
support for these patients is considerable and requires expertise
and training in the medical teams.
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